{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:05:26Z","timestamp":1784264726258,"version":"3.55.0"},"reference-count":273,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The tumor immune microenvironment (TIME), composed of tumor cells, immune\/stromal cells, cytokines, and other components, plays a central role in determining tumor immunogenicity and response to therapy. The balance between effector T\/NK cells and immunosuppressive populations such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and M2-like tumor-associated macrophages (TAMs) determines whether tumors remain \u201ccold\u201d or become \u201chot\u201d. Triple-negative breast cancer (TNBC) remains challenging to treat because it lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) targets and exhibits high heterogeneity. To address these limitations, tumor microenvironment (TME)-targeted nanocarriers have emerged as a promising strategy. By exploiting features such as hypoxia, acidity, redox imbalance, and abnormal vascular and mechanical cues, these systems enable prolonged circulation, active targeting, and stimulus-responsive release, thereby enhancing the efficacy of therapies such as immune checkpoint blockade. This review summarizes major nanoplatforms and therapeutic strategies, while highlighting translational barriers including TIME heterogeneity, enhanced permeability and retention (EPR) effect, and protein corona formation. Finally, this review explains why patient stratification should be incorporated into the future development of TNBC nano-immunotherapy and argues for simplified, reproducible nanocarrier designs to support clinically applicable precision treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1793737","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:23:08Z","timestamp":1784262188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Latest advances in nanodrug delivery systems for modulating the immune microenvironment in triple-negative breast cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoya","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Immunology, Medical School, Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxin","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Andrology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical School, Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Wu","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical School, Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical School, Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical School, Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical School, Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Andrology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical School, Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical School, Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.016","article-title":"Innate immune cells in the tumor microenvironment","volume":"39","author":"Li","year":"2021","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2022.07.006","article-title":"Cancer-associated fibroblasts: vital suppressors of the immune response in the tumor microenvironment","volume":"67","author":"Xiang","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217728","article-title":"SENP1-sirt3 axis promotes cholesterol biosynthesis in tumor-associated macrophages to suppress anti-tumor immunity","volume":"623","author":"Peng","year":"2025","journal-title":"Cancer Lett"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to pd-l1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0400-z","article-title":"Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy","volume":"41","author":"Gao","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (time) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"crossref","first-page":"106477","DOI":"10.1016\/j.intimp.2020.106477","article-title":"Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures","volume":"83","author":"Wu","year":"2020","journal-title":"International immunopharmacology"},{"key":"B15","doi-asserted-by":"crossref","first-page":"938134","DOI":"10.3389\/fphar.2022.938134","article-title":"Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis","volume":"13","author":"Yang","year":"2022","journal-title":"Frontiers in pharmacology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ t cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding cd8+ t cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory t cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01746-8","article-title":"Targeting jmjd1c to selectively disrupt tumor treg cell fitness enhances antitumor immunity","volume":"25","author":"Long","year":"2024","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-022-01002-x","article-title":"Metabolic communication in the tumour\u2013immune microenvironment","volume":"24","author":"Kao","year":"2022","journal-title":"Nat Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00547-1","article-title":"A timeline of tumour-associated macrophage biology","volume":"23","author":"Cassetta","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126046","article-title":"Immunotherapy transforms cancer treatment","volume":"129","author":"Zaidi","year":"2018","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx170","article-title":"Avelumab: clinical trial innovation and collaboration to advance anti-pd-l1 immunotherapy","volume":"28","author":"Chin","year":"2017","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217699","article-title":"Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited \u2013 exploring the \u201cspace","volume":"622","author":"Br\u00e4utigam","year":"2025","journal-title":"Cancer Lett"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-024-00506-6","article-title":"Enhanced cellular therapy: revolutionizing adoptive cellular therapy","volume":"13","author":"Xu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12276","article-title":"Combination of anti\u2010pd\u2010l1 antibody with peptide mel\u2010dkla targeting m2 tumor\u2010associated macrophages suppresses breast cancer metastasis","volume":"42","author":"Lee","year":"2022","journal-title":"Cancer Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by ctla-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of pd-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013pd-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0388-4","article-title":"Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients","volume":"30","author":"Pogoda","year":"2013","journal-title":"Med Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.NONRNA12-A25","article-title":"Abstract a25: differences in microrna expression patterns in breast cancer subtypes","volume":"72","author":"Romero-Cordoba","year":"2012","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-025-01436-x","article-title":"Transferrin receptors","volume":"57","author":"Guo","year":"2025","journal-title":"Exp Mol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.607692","article-title":"Antibodies targeting the transferrin receptor 1 (tfr1) as direct anti-cancer agents","volume":"12","author":"Candelaria","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-022-00859-0","article-title":"Ferritin \u2013 a multifaceted protein scaffold for biotherapeutics","volume":"54","author":"Lee","year":"2022","journal-title":"Exp Mol Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106019","article-title":"Future of pd-1\/pd-l1 axis modulation for the treatment of triple-negative breast cancer","volume":"175","author":"Nakhjavani","year":"2022","journal-title":"Pharmacol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040633","article-title":"Triple-negative breast cancer systemic treatment: disruptive early-stage developments for overcoming stagnation in the advanced pipeline","volume":"17","author":"Alonso-Ron","year":"2025","journal-title":"Cancers"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102672","article-title":"Breaking barriers in triple negative breast cancer (tnbc) \u2013 unleashing the power of antibody-drug conjugates (adcs)","volume":"123","author":"Dri","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmatsci.2023.101070","article-title":"Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer","volume":"134","author":"Kong","year":"2023","journal-title":"Prog Mater Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (keynote-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline brca mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-024-02047-2","article-title":"Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation car-t cell immunotherapy and beyond","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment\u2019s role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3596","article-title":"Infiltrating mast cell\u2013mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype","volume":"80","author":"Majorini","year":"2020","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-10004-2","article-title":"Individualized mrna vaccines evoke durable t cell immunity in adjuvant tnbc","volume":"651","author":"Sahin","year":"2026","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106036","article-title":"Improving the ability of car-t cells to hit solid tumors: challenges and strategies","volume":"175","author":"Zhang","year":"2022","journal-title":"Pharmacol Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B66","article-title":"Emerging Antibacterial Strategies with Application of Targeting Drug Delivery System and Combined Treatment","volume":"16","author":"Zhang","year":"","journal-title":"International journal of nanomedicine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114462","article-title":"Self-assembling nanocarriers from engineered proteins: design, functionalization, and application for drug delivery","volume":"189","author":"Li","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2021.02.037","article-title":"Bioactive nanotherapeutic trends to combat triple negative breast cancer","volume":"6","author":"Chowdhury","year":"2021","journal-title":"Bioact Mater"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.07.001","article-title":"A bioinspired doxorubicin-carried albumin nanocage against aggressive cancer via systemic targeting of tumor and lymph node metastasis","volume":"372","author":"Iqbal","year":"2024","journal-title":"J Controlled Release"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41467-024-45609-0","article-title":"Structural optimization of sirna conjugates for albumin binding achieves effective mcl1-directed cancer therapy","volume":"15","author":"Hoogenboezem","year":"2024","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2022.213224","article-title":"Injectable anti-cancer drug loaded silk-based hydrogel for the prevention of cancer recurrence and post-lumpectomy tissue regeneration aiding triple-negative breast cancer therapy","volume":"145","author":"Jaiswal","year":"2023","journal-title":"Biomater Adv"},{"key":"B72","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/adfm.201201238","article-title":"Self\u2010assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancer","volume":"23","author":"Seib","year":"2013","journal-title":"Adv Funct Mater"},{"key":"B73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2023.07.006","article-title":"Strategies to prolong drug retention in solid tumors by aggregating Endo-CMC nanoparticles","volume":"360","author":"Xia","year":"2023","journal-title":"Journal of controlled release : official journal of the Controlled Release Society"},{"key":"B74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.phrs.2016.03.002","article-title":"Ferritin nanocages: a biological platform for drug delivery, imaging and theranostics in cancer","volume":"107","author":"Truffi","year":"2016","journal-title":"Pharmacol Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1021\/acsanm.5c03120","article-title":"Antitumor efficacy and immunomodulation of h-ferritin nanocaged doxorubicin for triple negative breast cancer","volume":"8","author":"Truffi","year":"2025","journal-title":"ACS Appl Nano Mater"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.164697","article-title":"Ferritin nanocages facilitate protac delivery for enhanced targeted therapy in triple-negative breast cancer","volume":"518","author":"Xu","year":"2025","journal-title":"Chem Eng J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114030","article-title":"Bioengineering of virus-like particles as dynamic nanocarriers for in vivo delivery and targeting to solid tumours","volume":"180","author":"Suffian","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7150\/thno.103127","article-title":"Virus-like particle encapsulation of functional proteins: advances and applications","volume":"14","author":"Sun","year":"2024","journal-title":"Theranostics"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.163015","article-title":"Ultrasmall lactoferrin\/lipid multicompartmental nanomedicine-based reprogramming of glycolysis in triple-negative breast cancer via hdac6\/ldh axis enhances cancer immunotherapy","volume":"514","author":"Hassanin","year":"2025","journal-title":"Chem Eng J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.01.035","article-title":"Albumin-based delivery systems: recent advances, challenges, and opportunities","volume":"380","author":"Murphy","year":"2025","journal-title":"J Controlled Release"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41570-023-00486-x","article-title":"Silk chemistry and biomedical material designs","volume":"7","author":"Sahoo","year":"2023","journal-title":"Nat Rev Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115134","article-title":"Overcoming biological barriers by virus-like drug particles for drug delivery","volume":"203","author":"Chen","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202409194","article-title":"Interleukin 15-presenting nanovesicles with doxorubicin-loaded ferritin cores for cancer immunochemotherapy","volume":"12","author":"Zhai","year":"2025","journal-title":"Adv Sci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41467-023-44572-6","article-title":"Inhibition of irhom1 by cd44-targeting nanocarrier for improved cancer immunochemotherapy","volume":"15","author":"Luo","year":"2024","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202200824","article-title":"Gold\u2010nanoparticle\u2010mediated assembly of high\u2010order dna nano\u2010architectures","volume":"18","author":"Yin","year":"2022","journal-title":"Small"},{"key":"B86","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.9b01159","article-title":"Facile Construction of i-Motif DNA-Conjugated Gold Nanostars as Near-Infrared and pH Dual-Responsive Targeted Drug Delivery Systems for Combined Cancer Therapy","volume":"17","author":"Miao","year":"2020","journal-title":"Molecular pharmaceutics"},{"key":"B87","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12598-017-0949-y","article-title":"Controlled synthesis of silver nanoplates and nanoparticles by reducing silver nitrate with hydroxylamine hydrochloride","volume":"36","author":"Cheng","year":"2017","journal-title":"Rare Met"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122608","article-title":"Shikonin and chitosan-silver nanoparticles synergize against triple-negative breast cancer through ripk3-triggered necroptotic immunogenic cell death","volume":"309","author":"Liang","year":"2024","journal-title":"Biomaterials"},{"key":"B89","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cis.2019.01.003","article-title":"Magnetic nanocarriers: evolution of spinel ferrites for medical applications","volume":"265","author":"Amiri","year":"2019","journal-title":"Adv Colloid Interface Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.mattod.2021.08.002","article-title":"Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer","volume":"50","author":"Mu","year":"2021","journal-title":"Mater Today"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S426849","article-title":"The therapeutic effects of muc1-c shrna@fe3o4 magnetic nanoparticles in alternating magnetic fields on triple-negative breast cancer","volume":"18","author":"Li","year":"2023","journal-title":"Int J Nanomed"},{"key":"B92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12645-025-00323-4","article-title":"Polyaniline-coated iron oxide nanoparticles reprogram macrophages and modulate the tumor microenvironment to inhibit breast cancer progression and metastasis","volume":"16","author":"Nascimento","year":"2025","journal-title":"Cancer Nanotechnol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122395","article-title":"Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles","volume":"303","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202301307","article-title":"Simultaneous delivery of doxorubicin and ezh2-targeting sirna by vortex magnetic nanorods synergistically improved anti-tumor efficacy in triple-negative breast cancer","volume":"19","author":"Lu","year":"2023","journal-title":"Small"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116624","article-title":"EZH2: the roles in targeted therapy and mechanisms of resistance in breast cancer","volume":"175","author":"Chen","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.7b10699","article-title":"Injectable and self-healing thermosensitive magnetic hydrogel for asynchronous control release of doxorubicin and docetaxel to treat triple-negative breast cancer","volume":"9","author":"Xie","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1039\/C9NR01277J","article-title":"Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells","volume":"11","author":"Ruenraroengsak","year":"2019","journal-title":"Nanoscale"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1039\/D4TB02125H","article-title":"Combination of adenosine blockade and ferroptosis for photo-immunotherapy of triple negative breast cancer with aptamer-modified copper sulfide","volume":"13","author":"Zhang","year":"2025","journal-title":"J Mater Chem B"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201900820","article-title":"Hydrophobic metal\u2013organic frameworks","volume":"31","author":"Jayaramulu","year":"2019","journal-title":"Adv Mater"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124665","article-title":"Transferrin-conjugated uio-66 metal organic frameworks loaded with doxorubicin and indocyanine green: a multimodal nanoplatform for chemo-photothermal-photodynamic approach in cancer management","volume":"665","author":"Soman","year":"2024","journal-title":"Int J Pharm"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/cryst11040344","article-title":"Green synthesis and biomedical applications of zno nanoparticles: role of pegylated-zno nanoparticles as doxorubicin drug carrier against mda-mb-231(tnbc) cells line","volume":"11","author":"Batool","year":"2021","journal-title":"Crystals"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.10.044","article-title":"Tailored-cuo-nanowire decorated with folic acid mediated coupling of the mitochondrial-ros generation and mir425-pten axis in furnishing potent anti-cancer activity in human triple negative breast carcinoma cells","volume":"76","author":"Ahir","year":"2016","journal-title":"Biomaterials"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultsonch.2021.105497","article-title":"Understanding the relationship between particle size and ultrasonic treatment during the synthesis of metal nanoparticles","volume":"73","author":"Yang","year":"2021","journal-title":"Ultrason Sonochem"},{"key":"B104","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.1038\/s41467-021-27559-z","article-title":"Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis","volume":"12","author":"Ramchandani","year":"2021","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","first-page":"101982","DOI":"10.1016\/j.cis.2019.07.003","article-title":"Magnetically retrievable ferrite nanoparticles in the catalysis application","volume":"271","author":"Amiri","year":"2019","journal-title":"Adv Colloid Interface Sci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202508801","article-title":"Seed\u2010engineered growth of sub\u2010100 nm chiral au nanoparticles with enhanced optical chirality and catalytic activities","volume":"21","author":"Wan","year":"2025","journal-title":"Small"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2022.119736","article-title":"Linezolid nanoantiobiotics and sers-nanotags based on polymeric cyclodextrin bimetallic core-shell nanoarchitectures","volume":"293","author":"Hada","year":"2022","journal-title":"Carbohydr Polym"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwab045","article-title":"Light-emitting self-assembled metallacages","volume":"8","author":"Zhao","year":"2021","journal-title":"Natl Sci Rev"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115481","article-title":"Drug delivery using gold nanoparticles","volume":"216","author":"Dykman","year":"2025","journal-title":"Adv Drug Delivery Rev"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c00992","article-title":"Coupling gold nanospheres into nanochain constructs for high-contrast, longitudinal photoacoustic imaging","volume":"24","author":"Kim","year":"2024","journal-title":"Nano Lett"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.2c01100","article-title":"Synthesis and characterization of size- and charge-tunable silver nanoparticles for selective anticancer and antibacterial treatment","volume":"14","author":"Pucelik","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2025.160470","article-title":"Optimized silver nanostructures for enhanced antibacterial potential: recent trends and challenges in the development of metallo-antimicrobials","volume":"507","author":"Ali","year":"2025","journal-title":"Chem Eng J"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-024-00767-x","article-title":"Design of oxide nanoparticles for biomedical applications","volume":"10","author":"Lee","year":"2025","journal-title":"Nat Rev Mater"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115756","article-title":"Clinical translation and landscape of superparamagnetic iron oxide nanoparticles","volume":"229","author":"Li","year":"2026","journal-title":"Adv Drug Delivery Rev"},{"key":"B115","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40820-020-00423-3","article-title":"Metal\u2013organic framework nanocarriers for drug delivery in biomedical applications","volume":"12","author":"Sun","year":"2020","journal-title":"Nano Micro Lett"},{"key":"B116","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mser.2019.01.001","article-title":"Mesoporous silica\/organosilica nanoparticles: synthesis, biological effect and biomedical application","volume":"137","author":"Yang","year":"2019","journal-title":"Mater Sci Eng R Rep"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2021.214309","article-title":"Chemically engineered mesoporous silica nanoparticles-based intelligent delivery systems for theranostic applications in multiple cancerous\/non-cancerous diseases","volume":"452","author":"Zhou","year":"2022","journal-title":"Coord Chem Rev"},{"key":"B118","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B119","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer \u2014 expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jconrel.2021.07.029","article-title":"Advanced mesoporous silica nanocarriers in cancer theranostics and gene editing applications","volume":"337","author":"\u017divojevi\u0107","year":"2021","journal-title":"J Controlled Release"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01932-1","article-title":"Analysis of multi-drug cancer nanomedicine","volume":"20","author":"Benderski","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2020.102157","article-title":"Biodegradable calcium phosphate nanoparticles for cancer therapy","volume":"279","author":"Khalifehzadeh","year":"2020","journal-title":"Adv Colloid Interface Sci"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28124790","article-title":"Calcium phosphate-based nanomaterials: preparation, multifunction, and application for bone tissue engineering","volume":"28","author":"Chen","year":"2023","journal-title":"Molecules"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01424-8","article-title":"Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies","volume":"125","author":"Wang","year":"2021","journal-title":"Br J Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41413-024-00356-2","article-title":"Bone targeted nano-drug and nano-delivery","volume":"12","author":"Wu","year":"2024","journal-title":"Bone Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.05.038","article-title":"Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression","volume":"166","author":"Liu","year":"2023","journal-title":"Acta Biomater"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2016.02.027","article-title":"Effect of sicl4 on the preparation of functionalized mixed-structure silica from monodisperse sol\u2013gel silica nanoparticles","volume":"292","author":"Moreno","year":"2016","journal-title":"Chem Eng J"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030118","article-title":"Mesoporous silica nanoparticles: a comprehensive review on synthesis and recent advances","volume":"10","author":"Narayan","year":"2018","journal-title":"Pharmaceutics"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/adma.200702010","article-title":"Highly ordered arrays of mesoporous silica nanorods with tunable aspect ratios from block copolymer thin films","volume":"20","author":"Chen","year":"2008","journal-title":"Adv Mater"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2023.10.008","article-title":"Calcium-based biomaterials: unveiling features and expanding applications in osteosarcoma treatment","volume":"32","author":"Wu","year":"2024","journal-title":"Bioact Mater"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1039\/C8CS00489G","article-title":"Biomolecule-assisted green synthesis of nanostructured calcium phosphates and their biomedical applications","volume":"48","author":"Qi","year":"2019","journal-title":"Chem Soc Rev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1039\/C6RA10659E","article-title":"Citrate-functionalized hydroxyapatite nanoparticles for ph-responsive drug delivery","volume":"6","author":"Verma","year":"2016","journal-title":"RSC Adv"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2024.101497","article-title":"Hydroxyapatite modified poly(acrylic acid)\/polyethylene glycol sustainable drug delivery nanocomposite prepared via double emulsion with bitter almond oil","volume":"38","author":"Aslani","year":"2024","journal-title":"Sustain Chem Pharm"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2013.08.016","article-title":"Graphene and graphene oxide as new nanocarriers for drug delivery applications","volume":"9","author":"Liu","year":"2013","journal-title":"Acta Biomater"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103521","article-title":"Polyethylenimine modified graphene oxide for effective chemo-gene-photothermal triples therapy of triple-negative breast cancer and inhibits metastasis","volume":"74","author":"Chen","year":"2022","journal-title":"J Drug Delivery Sci Technol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213550","article-title":"Polymeric graphene oxide nanoparticles loaded with doxorubicin for combined photothermal and chemotherapy in triple negative breast cancer","volume":"153","author":"Itoo","year":"2023","journal-title":"Biomater Adv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1021\/nn2003508","article-title":"Virtual issue on nanomaterials for drug delivery","volume":"5","author":"Hammond","year":"2011","journal-title":"ACS Nano"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.colcom.2020.100235","article-title":"CD44 receptor targeted \u2018smart\u2019 multi-walled carbon nanotubes for synergistic therapy of triple-negative breast cancer","volume":"35","author":"Singhai","year":"2020","journal-title":"Colloid Interface Sci Commun"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.matchemphys.2024.128981","article-title":"Carbon quantum dot based nanocarrier labeled with anti-pdl1 antibody as a promising theranostic candidate for the triple negative breast cancer treatment","volume":"315","author":"Azizi","year":"2024","journal-title":"Mater Chem Phys"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/ma18092139","article-title":"CD44 receptor-mediated ferroptosis induction by hyaluronic acid carbon quantum dots in triple-negative breast cancer cells through downregulation of slc7a11 pathway","volume":"18","author":"Chandrasekaran","year":"2025","journal-title":"Materials"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2024.216247","article-title":"Graphene quantum dots as nanotherapeutic agents for triple-negative breast cancer: insights from 3d tumor models","volume":"523","author":"Dar","year":"2025","journal-title":"Coord Chem Rev"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201902817","article-title":"New concepts for production of scalable single layer oxidized regions by local anodic oxidation of graphene","volume":"15","author":"Quesada","year":"2019","journal-title":"Small"},{"key":"B143","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12951-019-0525-8","article-title":"Small molecules derived carbon dots: synthesis and applications in sensing, catalysis, imaging, and biomedicine","volume":"17","author":"Sharma","year":"2019","journal-title":"J Nanobiotechnol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2020.111382","article-title":"Folic acid based carbon dot functionalized stearic acid-g-polyethyleneimine amphiphilic nanomicelle: targeted drug delivery and imaging for triple negative breast cancer","volume":"197","author":"Sarkar","year":"2021","journal-title":"Colloids Surf B"},{"key":"B145","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12951-021-00811-w","article-title":"NIR-laser-triggered gadolinium-doped carbon dots for magnetic resonance imaging, drug delivery and combined photothermal chemotherapy for triple negative breast cancer","volume":"19","author":"Jiang","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201603276","article-title":"Black phosphorus nanosheets as a robust delivery platform for cancer theranostics","volume":"29","author":"Tao","year":"2017","journal-title":"Adv Mater"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1039\/D1CS00659B","article-title":"Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades","volume":"51","author":"Vallet-Reg\u00ed","year":"2022","journal-title":"Chem Soc Rev"},{"key":"B148","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41392-023-01654-7","article-title":"Multifunctional mesoporous silica nanoparticles for biomedical applications","volume":"8","author":"Xu","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100501","article-title":"Preparation and application of calcium phosphate nanocarriers in drug delivery","volume":"17","author":"Qiu","year":"2022","journal-title":"Mater Today Bio"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c09608","article-title":"Improved cap nanoparticles for nucleic acid and protein delivery to neural primary cultures and stem cells","volume":"18","author":"Chao","year":"2024","journal-title":"ACS Nano"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.7150\/thno.70721","article-title":"Recent progress of carbon dots in targeted bioimaging and cancer therapy","volume":"12","author":"Shen","year":"2022","journal-title":"Theranostics"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115644","article-title":"Carbon dots in drug delivery and therapeutic applications","volume":"224","author":"Singh","year":"2025","journal-title":"Adv Drug Delivery Rev"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1038\/s41467-022-30185-y","article-title":"Polymer-coated carbon nanotube hybrids with functional peptides for gene delivery into plant mitochondria","volume":"13","author":"Law","year":"2022","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114100","article-title":"Recent developments in the use of carbon-based nanomaterials in cancer therapy","volume":"386","author":"Algarra","year":"2025","journal-title":"J Controlled Release"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1039\/D4CS00007B","article-title":"Black phosphorus-based nanoplatforms for cancer therapy: chemistry, design, biological and therapeutic behaviors","volume":"54","author":"Bigham","year":"2025","journal-title":"Chem Soc Rev"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1039\/D3TB00723E","article-title":"Antibacterial black phosphorus nanosheets for biomedical applications","volume":"11","author":"Xu","year":"2023","journal-title":"J Mater Chem B"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114467","article-title":"Cellular and subcellular interactions of graphene-based materials with cancerous and non-cancerous cells","volume":"189","author":"Rahimi","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B158","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2022.08.011","article-title":"Multifunctional graphene oxide nanoparticles for drug delivery in cancer","volume":"350","author":"Itoo","year":"2022","journal-title":"J Controlled Release"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.pecs.2023.101097","article-title":"MXene-based heterostructures: current trend and development in electrochemical energy storage devices","volume":"97","author":"Hussain","year":"2023","journal-title":"Prog Energy Combust Sci"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201604508","article-title":"A nano-in-nano vector: merging the best of polymeric nanoparticles and drug nanocrystals","volume":"27","author":"Liu","year":"2017","journal-title":"Adv Funct Mater"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01201-6","article-title":"Recent advances in extracellular vesicles for therapeutic cargo delivery","volume":"56","author":"Kim","year":"2024","journal-title":"Exp Mol Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124639","article-title":"Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: current status and future perspectives","volume":"664","author":"Bazzazan","year":"2024","journal-title":"Int J Pharm"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(89)90281-0","article-title":"Nanocapsule formation by interfacial polymer deposition following solvent displacement","volume":"55","author":"Fessi","year":"1989","journal-title":"Int J Pharm"},{"key":"B164","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.progpolymsci.2011.01.001","article-title":"Polymer nanoparticles: preparation techniques and size-control parameters","volume":"36","author":"Rao","year":"2011","journal-title":"Prog Polym Sci"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1039\/D5SM00006H","article-title":"Recent advances in nanoprecipitation: from mechanistic insights to applications in nanomaterial synthesis","volume":"21","author":"Kuddushi","year":"2025","journal-title":"Soft Matter"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.6b01114","article-title":"Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis","volume":"10","author":"Kamaly","year":"2016","journal-title":"ACS Nano"},{"key":"B167","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1038\/s41467-019-11730-8","article-title":"Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence","volume":"10","author":"Song","year":"2019","journal-title":"Nat Commun"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-025-00347-w","article-title":"Dendrimer engineering to overcome delivery challenges of nucleic acids","volume":"3","author":"Ni","year":"2025","journal-title":"Nat Rev Bioeng"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115136","article-title":"Lipid nanoparticles for targeted delivery of anticancer therapeutics: recent advances in development of sirna and lipoprotein-mimicking nanocarriers","volume":"203","author":"Yaghmur","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2022.12.027","article-title":"Functionalized liposomes for targeted breast cancer drug delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioact Mater"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2022.05.037","article-title":"Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic\/chemo-\/immunotherapy","volume":"20","author":"Li","year":"2023","journal-title":"Bioact Mater"},{"key":"B172","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363185","article-title":"Defining tropism and activity of natural and engineered extracellular vesicles","volume":"15","author":"Choi","year":"2024","journal-title":"Front Immunol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.143454","article-title":"Activated t cell-derived exosomes for targeted delivery of axl-sirna loaded paclitaxel-poly-l-lysine prodrug to overcome drug resistance in triple-negative breast cancer","volume":"468","author":"Chen","year":"2023","journal-title":"Chem Eng J"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.05.027","article-title":"Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake","volume":"347","author":"Kimiz-Gebologlu","year":"2022","journal-title":"J Controlled Release"},{"key":"B176","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","article-title":"Targeting drugs to tumours using cell membrane-coated nanoparticles","volume":"20","author":"Fang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1038\/s41467-022-33889-3","article-title":"Systematic design of cell membrane coating to improve tumor targeting of nanoparticles","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem Rev"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1039\/D5NR00071H","article-title":"Characterisation of polymeric nanoparticles for drug delivery","volume":"17","author":"Floyd","year":"2025","journal-title":"Nanoscale"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102147","article-title":"Rational design of polymeric micelles for targeted therapeutic delivery","volume":"55","author":"Zheng","year":"2024","journal-title":"Nano Today"},{"key":"B181","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jconrel.2021.04.014","article-title":"Harnessing amphiphilic polymeric micelles for diagnostic and therapeutic applications: breakthroughs and bottlenecks","volume":"334","author":"Kaur","year":"2021","journal-title":"J Controlled Release"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1039\/D2CS00247G","article-title":"Bioengineered nanogels for cancer immunotherapy","volume":"51","author":"Ma","year":"2022","journal-title":"Chem Soc Rev"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2025.102645","article-title":"Nanogels: a chemically versatile drug delivery platform","volume":"61","author":"Blagojevic","year":"2025","journal-title":"Nano Today"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv Drug Delivery Rev"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00902-w","article-title":"Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy","volume":"43","author":"Mukherjee","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2500from liposomes to mrna vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00410-w","article-title":"Therapeutically harnessing extracellular vesicles","volume":"21","author":"Cheng","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B190","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-023-01849-0","article-title":"Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics","volume":"22","author":"Gajbhiye","year":"2023","journal-title":"Mol Cancer"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201600356","article-title":"Periodic mesoporous organosilica coated pRussian blue for mr\/pa dual-modal imaging-guided photothermal-chemotherapy of triple negative breast cancer","volume":"4","author":"Tian","year":"2017","journal-title":"Adv Sci"},{"key":"B192","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12951-021-01202-x","article-title":"Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer","volume":"19","author":"Chen","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010246","article-title":"Recent advances in targeted nanocarriers for the management of triple negative breast cancer","volume":"15","author":"Pradhan","year":"2023","journal-title":"Pharmaceutics"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.7b00974","article-title":"H-ferritin enriches the curcumin uptake and improves the therapeutic efficacy in triple negative breast cancer cells","volume":"18","author":"Pandolfi","year":"2017","journal-title":"Biomacromolecules"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122734","article-title":"CD44-receptor targeted gold-doxorubicin nanocomposite for pulsatile chemo-photothermal therapy of triple-negative breast cancer cells","volume":"14","author":"Kalyane","year":"2022","journal-title":"Pharmaceutics"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.10.001","article-title":"Photoimmunotherapy with cetuximab-conjugated gold nanorods reduces drug resistance in triple negative breast cancer spheroids with enhanced infiltration of tumor-associated macrophages","volume":"329","author":"Emami","year":"2021","journal-title":"J Controlled Release"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124625","article-title":"A self-targeting mofs nanoplatform for treating metastatic triple-negative breast cancer through tumor microenvironment remodeling and chemotherapy potentiation","volume":"664","author":"Wu","year":"2024","journal-title":"Int J Pharm"},{"key":"B198","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40824-023-00447-x","article-title":"Metal-organic framework-based photodynamic combined immunotherapy against the distant development of triple-negative breast cancer","volume":"27","author":"Liang","year":"2023","journal-title":"Biomater Res"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1039\/D0BM00015A","article-title":"Delivery of dual mirna through cd44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy","volume":"8","author":"Ahir","year":"2020","journal-title":"Biomater Sci"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2016.07.016","article-title":"Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and mir-221\/222 inhibitors","volume":"13","author":"Zhou","year":"2017","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S418100","article-title":"Co-delivery nanomicelles for potentiating tnbc immunotherapy by synergetically reshaping cafs-mediated tumor stroma and reprogramming immunosuppressive microenvironment","volume":"18","author":"Zhang","year":"2023","journal-title":"Int J Nanomed"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112432","article-title":"Advancements in polymeric nanocarriers to mediate targeted therapy against triple-negative breast cancer","volume":"14","author":"Fatima","year":"2022","journal-title":"Pharmaceutics"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav5010","article-title":"Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis","volume":"5","author":"Guo","year":"2019","journal-title":"Sci Adv"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070926","article-title":"Combinatorial delivery of docetaxel- and erlotinib-loaded functionalized nanostructured lipid carriers for the treatment of triple-negative breast cancer using quality-by-design approach","volume":"16","author":"Chaudhuri","year":"2024","journal-title":"Pharmaceutics"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1039\/D0NR00523A","article-title":"Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer","volume":"12","author":"Li","year":"2020","journal-title":"Nanoscale"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1039\/D4NR00284A","article-title":"Cell membrane coated nanoparticles as a biomimetic drug delivery platform for enhancing cancer immunotherapy","volume":"16","author":"Zhong","year":"2024","journal-title":"Nanoscale"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00242","article-title":"Combination nano-delivery systems remodel the immunosuppressive tumor microenvironment for metastatic triple-negative breast cancer therapy","volume":"21","author":"Bai","year":"2024","journal-title":"Mol Pharm"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S408855","article-title":"Multifunctional nanoplatform-mediated chemo-photothermal therapy combines immunogenic cell death with checkpoint blockade to combat triple-negative breast cancer and distant metastasis","volume":"18","author":"Zhu","year":"2023","journal-title":"Int J Nanomed"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B210","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"biomark Res"},{"key":"B211","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1038\/s41467-022-34744-1","article-title":"Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models","volume":"13","author":"Panagi","year":"2022","journal-title":"Nat Commun"},{"key":"B212","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-pd1 treatment and capture distinct paths of t cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat Commun"},{"key":"B213","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer Cell"},{"key":"B214","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.03.039","article-title":"Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis","volume":"333","author":"Gu","year":"2021","journal-title":"J Controlled Release"},{"key":"B216","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","article-title":"A randomized phase 3 trial of gemcitabine or nab-paclitaxel combined with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase iii trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil\u2013based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S123437","article-title":"Nanomedicine applications in the treatment of breast cancer: current state of the art","volume":"12","author":"Wu","year":"2017","journal-title":"IJN"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-020-00034-4","article-title":"Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center","volume":"32","author":"Khallaf","year":"2020","journal-title":"J Egypt Natl Cancer Inst"},{"key":"B220","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/wnan.1343","article-title":"Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances","volume":"7","author":"Miller-Kleinhenz","year":"2015","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu025","article-title":"A randomized controlled phase ii trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (tnbc)","volume":"25","author":"Awada","year":"2014","journal-title":"Ann Oncol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-pd-l1\/ctla-4 bispecific antibody kn046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase ii trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: impassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0424-4","article-title":"Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00551-z","article-title":"Nanomaterial-encapsulated sting agonists for immune modulation in cancer therapy","volume":"12","author":"Chen","year":"2024","journal-title":"biomark Res"},{"key":"B226","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.7150\/thno.69119","article-title":"Anti-pd-l1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining pd-l1 blockade with immunogenic cell death","volume":"12","author":"Moon","year":"2022","journal-title":"Theranostics"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201804882","article-title":"Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy","volume":"58","author":"Duan","year":"2019","journal-title":"Angew Chem Int Ed"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.08.010","article-title":"Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy","volume":"10","author":"Zhu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2017.10.013","article-title":"Biodegradable sting agonist nanoparticles for enhanced cancer immunotherapy","volume":"14","author":"Wilson","year":"2018","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"B230","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/cd73\/a2ar pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009160","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.01.075","article-title":"Engineering nanoparticles boost tnbc therapy by cd24 blockade and mitochondrial dynamics regulation","volume":"355","author":"Zhao","year":"2023","journal-title":"J Controlled Release"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2022.101651","article-title":"Nanoparticle-enabled concurrent modulation of phagocytosis and repolarization of macrophages for enhanced cancer immunotherapy","volume":"47","author":"Zhang","year":"2022","journal-title":"Nano Today"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122905","article-title":"Biologically logic-gated trojan-horse strategy for personalized triple-negative breast cancer precise therapy by selective ferroptosis and sting pathway provoking","volume":"315","author":"Guo","year":"2025","journal-title":"Biomaterials"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122960","article-title":"A positive-feedback loop suppresses tnbc tumour growth by remodeling tumour immune microenvironment and inducing ferroptosis","volume":"315","author":"Ye","year":"2025","journal-title":"Biomaterials"},{"key":"B236","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","article-title":"Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific cebpb isoform in triple-negative breast cancer","volume":"28","author":"Li","year":"2018","journal-title":"Cell Metab"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx730","article-title":"Clinical significance of cd73 in triple-negative breast cancer: multiplex analysis of a phase iii clinical trial","volume":"29","author":"Buisseret","year":"2018","journal-title":"Ann Oncol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222251110","article-title":"CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer","volume":"110","author":"Loi","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.12.022","article-title":"Site-specific controlled-release nanoparticles for immune reprogramming via dual metabolic inhibition against triple-negative breast cancer","volume":"366","author":"She","year":"2024","journal-title":"J Controlled Release"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by t and nk cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S513207","article-title":"Reprogramming of glucose metabolism by nanocarriers to improve cancer immunotherapy: recent advances and applications","volume":"20","author":"Jiang","year":"2025","journal-title":"IJN"},{"key":"B242","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s42003-021-02805-8","article-title":"DLST-dependence dictates metabolic heterogeneity in tca-cycle usage among triple-negative breast cancer","volume":"4","author":"Shen","year":"2021","journal-title":"Commun Biol"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.04.009","article-title":"Enhancing immunotherapy efficacy against mhc-i deficient triple-negative breast cancer using lcl161-loaded macrophage membrane-decorated nanoparticles","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210082","article-title":"Perspectives for improving the tumor targeting of nanomedicine via the epr effect in clinical tumors","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.09.041","article-title":"Preclinical imaging and translational animal models of cancer for accelerated clinical implementation of nanotechnologies and macromolecular agents","volume":"219","author":"De Souza","year":"2015","journal-title":"J Controlled Release"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114449","article-title":"Strategies to enhance drug delivery to solid tumors by harnessing the epr effects and alternative targeting mechanisms","volume":"188","author":"Zi","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2023.103045","article-title":"Progress and challenges in the translation of cancer nanomedicines","volume":"85","author":"Tong","year":"2024","journal-title":"Curr Opin Biotechnol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug Delivery Transl Res"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100208","article-title":"Towards principled design of cancer nanomedicine to accelerate clinical translation","volume":"13","author":"Souri","year":"2022","journal-title":"Mater Today Bio"},{"key":"B250","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.apsb.2024.12.007","article-title":"Recent advances in the bench-to-bedside translation of cancer nanomedicines","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: an update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng Transl Med"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01754-7","article-title":"A translational framework to deliver nanomedicines to the clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-1756","article-title":"A review of the current understanding of nanoparticles protein corona composition","volume":"93","author":"Breznica","year":"2020","journal-title":"Med Pharm Rep"},{"key":"B254","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of tils in breast cancer: a report from the international immuno-oncology biomarker working group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B255","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021","journal-title":"Nat Commun"},{"key":"B256","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1186\/s12951-024-02954-y","article-title":"The role of patient-specific variables in protein corona formation and therapeutic efficacy in nanomedicine","volume":"22","author":"Cisneros","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor epr effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040609","article-title":"Breast density evaluation according to bi-rads 5th edition on digital breast tomosynthesis: ai automated assessment versus human visual assessment","volume":"13","author":"Tari","year":"2023","journal-title":"J Pers Med"},{"key":"B259","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2183\/pjab.88.53","article-title":"Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the epr effect for tumor-selective drug targeting","volume":"88","author":"Maeda","year":"2012","journal-title":"Proc Jpn Acad B"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114708","article-title":"Nanoparticle biodistribution coefficients: a quantitative approach for understanding the tissue distribution of nanoparticles","volume":"194","author":"Kumar","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.3390\/nano10112186","article-title":"Understanding nanoparticle toxicity to direct a safe-by-design approach in cancer nanomedicine","volume":"10","author":"Damasco","year":"2020","journal-title":"Nanomaterials"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603039","article-title":"Nanoparticle-induced complement activation: implications for cancer nanomedicine","volume":"11","author":"La-Beck","year":"2021","journal-title":"Front Immunol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.09.005","article-title":"Current state of nanomedicine drug products: an industry perspective","volume":"113","author":"Clogston","year":"2024","journal-title":"J Pharm Sci"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-024-01646-2","article-title":"Toward an international standardisation roadmap for nanomedicine","volume":"14","author":"Caputo","year":"2024","journal-title":"Drug Delivery Transl Res"},{"key":"B265","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: an industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv Drug Delivery Rev"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071821","article-title":"Biomimetic cell-derived nanoparticles: emerging platforms for cancer immunotherapy","volume":"15","author":"Hu","year":"2023","journal-title":"Pharmaceutics"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1561464","article-title":"Extracellular vesicles in triple-negative breast cancer: current updates, challenges and future prospects","volume":"12","author":"Tiwari","year":"2025","journal-title":"Front Mol Biosci"},{"key":"B268","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJN.S570252","article-title":"Extracellular vesicles as emerging drug delivery platforms in triple-negative breast cancer: a systematic review","volume":"21","author":"Tian","year":"2026","journal-title":"Int J Nanomed"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.70027","article-title":"Machine learning and artificial intelligence in nanomedicine","volume":"17","author":"Chou","year":"2025","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.126094","article-title":"A review on protein corona formation on nanoparticles and prediction of its composition using artificial intelligence tools","volume":"683","author":"Ahmadi","year":"2025","journal-title":"Int J Pharm"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1499301","article-title":"Spatial transcriptomics in breast cancer: providing insight into tumor heterogeneity and promoting individualized therapy","volume":"15","author":"An","year":"2024","journal-title":"Front Immunol"},{"key":"B272","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","article-title":"Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment","volume":"24","author":"Le","year":"2025","journal-title":"Mol Cancer"},{"key":"B273","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ccell.2022.09.001","article-title":"Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy","volume":"40","author":"Tcyganov","year":"2022","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1793737\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:23:11Z","timestamp":1784262191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1793737\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":273,"alternative-id":["10.3389\/fimmu.2026.1793737"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1793737","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1793737"}}